Back to Dashboard








Amgen Inc. (AMGN)
Real-time intraday values
Market Overview
From:
To:
AMGN Intraday
No data available
SymbolAMGN
IPO DateJun 17, 1983
CEOMr. Robert A. Bradway
Full Time Employees31.5k
SectorHealthcare
IndustryDrug Manufacturers - General
CountryUnited States
ExchangeNasdaqGS
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Performance
| Period | Return % | Value Change |
|---|---|---|
| 1 Day | -0.22% | -0.73 US$ |
| 5 Days | +0.34% | +1.15 US$ |
| 1 Month | -1.74% | -5.98 US$ |
| 6 Months | -1.74% | -6.00 US$ |
Analyzing Market with AI
Evaluating the last 30 days of history and fundamental metrics of AMGN...
Key Statistics
Market Cap
183.12B
P/E Ratio
23.58
Div Yield
297.00%
52W High
$391.29
52W Low
$267.83
Analyst Consensus
CONSENSUSBuy
BULLISH1440.0%
NEUTRAL1851.4%
BEARISH38.6%
52W Analyst Price Targets
Min Target
$200.00
$200.00
Max Target
$427.00
$427.00
Current$338.57
Avg Target$352.23
Analyst Recommendations
Precio Objetivo:$352.23($200.00 - $427.00)
Community Thoughts
Share your analysis and sentiment on AMGN
Join the community to share your analysis
Latest News for AMGN
Amgen (AMGN) Announces Retirement of CFO Peter Griffith
Insider Monkey•May 25, 2026, 07:54 PM
Honeywell-Backed Quantinuum Seeks to Raise $1.05 Billion in IPO
Bloomberg•May 26, 2026, 11:00 AM
3 Blue Chip Dividend Stocks to Buy in June as the Dow Jones Industrial Average Turns 130
Motley Fool•May 26, 2026, 07:20 AM
A Look At Amgen (AMGN) Valuation As Tavneos Safety Concerns And Withdrawal Requests Escalate
Simply Wall St.•May 22, 2026, 06:15 AM
Why Wall Street Thinks This Dividend Stock Could Jump 30%
Barchart•May 22, 2026, 05:32 PM
Amgen Inc. (AMGN): Navellier’s Long-Term Pick on Pipeline Strength and Sales Growth
Insider Monkey•May 21, 2026, 08:51 AM
CFOs On the Move: Week ending May 22
CFO.com•May 22, 2026, 08:49 AM
Amgen’s ‘boomerang’ CFO reaps $12.5M in cash, retention bonuses
CFO Dive•May 21, 2026, 02:35 PM
Amgen Drug Gets New Warnings in Japan After Patient Deaths
The Wall Street Journal•May 21, 2026, 10:24 AM
Argus Adjusts Price Target on Amgen to $375 From $400, Maintains Buy Rating
MT Newswires•May 20, 2026, 10:22 AM